This project is directed to the characterization of the recently described Siglec family of cell adhesion receptors, a subfamily of the immunoglobulin superfamily. The extracellular domains of the Siglecs have a homologous N-terminal Ig domain which confers the ability to bind to sialic acid containing carbohydrate groups of glycoproteins and glycolipids. To date, there are six known members of the family, five of which are expressed in cells of the immune system. Most is known about CD22 (Siglec 2), which has been implicated in dampening the immune response against autoantigens and autoimmune disease. In contrast to CD22, the detailed biology and functions of the other Siglecs are poorly understood. The primary goal of the project will be to characterize the detailed specificities of murine and human Siglecs towards sialyloligosaccharides of glycoproteins and glycolipids, and to develop multivalent sialyloligosaccharide probes unique to each Siglec that will aid in their identification and characterization in complex biological systems. The initial objective will be to establish the affinity and specificity of each of the six known Siglecs for 16 common sialyloligosaccharides found on carbohydrate groups of glycoproteins and glycolipids. The strategy will be to synthesize monovalent sialyloligosaccharides using a chemo-enzymatic approach, and establish the equilibrium dissociation constant for each Siglec using an assay employing surface plasmon resonance. This information will be used to design synthetic multivalent sialyloligosaccharide probes that distinguish each selectin in complex biological systems, and serve as tools in exploring their biological functions. A key biological resource to this project will be the availability of 'knockout mice' deficient in sialyltransferase genes involved in the synthesis of the sialoside ligands of Siglecs. These mice will aid in the evaluation of the functional status of Siglecs and provide insights into the role of these enzymes in the regulation of Siglec function.
| Chen, Weihsu C; Sigal, Darren S; Saven, Alan et al. (2012) Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22. Leuk Lymphoma 53:208-10 |
| Rhee, Jin-Kyu; Baksh, Michael; Nycholat, Corwin et al. (2012) Glycan-targeted virus-like nanoparticles for photodynamic therapy. Biomacromolecules 13:2333-8 |
| Rillahan, Cory D; Brown, Steven J; Register, Amy C et al. (2011) High-throughput screening for inhibitors of sialyl- and fucosyltransferases. Angew Chem Int Ed Engl 50:12534-7 |
| Zeng, Ying; Rademacher, Christoph; Nycholat, Corwin M et al. (2011) High affinity sialoside ligands of myelin associated glycoprotein. Bioorg Med Chem Lett 21:5045-9 |
| Rhee, Jin-Kyu; Hovlid, Marisa; Fiedler, Jason D et al. (2011) Colorful virus-like particles: fluorescent protein packaging by the Q? capsid. Biomacromolecules 12:3977-81 |
| Cui, Lina; Kitov, Pavel I; Completo, Gladys C et al. (2011) Supramolecular complexing of membane Siglec CD22 mediated by a polyvalent heterobifunctional ligand that templates on IgM. Bioconjug Chem 22:546-50 |
| Rillahan, Cory D; Paulson, James C (2011) Glycan microarrays for decoding the glycome. Annu Rev Biochem 80:797-823 |
| Abdu-Allah, Hajjaj H M; Watanabe, Kozo; Completo, Gladys C et al. (2011) CD22-antagonists with nanomolar potency: the synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold. Bioorg Med Chem 19:1966-71 |
| Belisle, Jennifer A; Horibata, Sachi; Jennifer, Gubbels A A et al. (2010) Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes. Mol Cancer 9:118 |
| Ramya, T N C; Weerapana, Eranthie; Liao, Lujian et al. (2010) In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics. Mol Cell Proteomics 9:1339-51 |
Showing the most recent 10 out of 41 publications
